Company news
Mustang Bio, Inc. news in 2023
Mustang Bio, Inc.'s news releases, calls and decks from 2023, newest first.
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
December 10, 2023
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 13, 2023
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
November 1, 2023
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
October 29, 2023
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
October 25, 2023
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
October 25, 2023
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
September 6, 2023
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
August 15, 2023
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 13, 2023
Mustang Bio to Participate in Two August 2023 Investor Conferences
August 2, 2023
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
July 30, 2023
Mustang Bio Announces Participation in Upcoming Scientific Meetings
July 5, 2023
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 14, 2023
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 11, 2023
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
May 17, 2023
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
May 10, 2023
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 28, 2023
Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 27, 2023
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
January 16, 2023